Clinical Trial Update: Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT [Phase 1]

View source ↗

Summary

Phase I trial of LDE225 (sonidegib) for steroid-refractory chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• LDE225 (sonidegib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Graft Versus Host Disease | Phase 1 | Status: TERMINATED